

# NOVARTIS MULTIDISCIPLINARY MEETING

**Meeting Objective:** To educate and update GPs about management and treatment of three disease states – Psoriasis, Heart Failure and Multiple Sclerosis



**DATE:** Saturday, 12<sup>th</sup> June, 2021

**TIME:** 10:00am – 1:30pm

**VENUE:** Pullman Cairns International  
Private Function Room  
17 Abbott St  
Cairns City QLD 4870

## SPEAKERS:

Dr Iisphi Browne – Dermatologist

Dr Sam Hillier - Cardiologist

Dr Michael Boggild - Neurologist

TIME	AGENDA	SPEAKER
10:00 AM	Arrival and Registration	
10:30 AM	Welcome	Novartis
10:35 AM	The management of Psoriasis and the latest updates on biologics	Dr Iisphi Browne
11:15 AM	Heart Failure – Act now to optimise treatment and improve quality of life for your patients with HF-rEF	Dr Sam Hillier
12:00 PM	Lunch	
12:45 PM	Updates on Multiple Sclerosis	Dr Michael Boggild
1:30 PM	Meeting close	

**RSVP** by Friday, 11<sup>th</sup> June 2021

To register your attendance, please see details overleaf.

# NOVARTIS MULTIDISCIPLINARY MEETING



TO REGISTER YOUR ATTENDANCE,  
SCAN THE QR CODE  
OR GO ONLINE: <https://evt.to/oggmagew>



FOR ANY QUESTIONS REGARDING THE MEETING,  
PLEASE CONTACT:  
Jayne Owen on 0449 564 635 or Jenny Chan on 0404 166 759

## **Privacy Information**

Your personal information will be processed in accordance with the Novartis Privacy Policy at <https://www.novartis.com.au/privacy-policy>.

Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.

Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.

In accordance with the Code of Conduct for the prescription medicine industry in Australia, any costs (for example travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by the company.

Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. May 2021. AU-16487.